Andrew McConaghie
Senior Writer
Andrew is a London-based journalist who has been writing about pharma, biotech and healthcare for over 20 years.
He writes on a range of topics, including biopharma R&D and commercial issues, digital healthcare and issues affecting patients and global healthcare systems, especially the UK’s NHS.
Latest From Andrew McConaghie
ESMO: Novel Checkpoint Inhibitors From Merck And BMS Show Promise
TIGIT is not the only novel IO mechanism showing promise, with market leaders Merck and BMS showcasing data from other early stage combinations with Opdivo and Keytruda, while Servier presented a possible three-way combo.
ESMO: Merck Sees Keytruda-Lenvima Potential In Melanoma, Hard-To-Treat Cancers
Keytruda-Lenvima picked out as pick of combination therapies from the European cancer congress.
Roche’s Ipatasertib Promising In Prostate, But Disappointing In Breast Cancer
Roche is hoping the investigational oral drug can help it expand its presence in breast cancer and break into the prostate cancer market – but the signals are decidedly mixed.
'A New TNBC Standard Of Care' – Trodelvy Could Vindicate Gilead’s $21bn Buyout
Analysts agree that new Phase III data suggests the antibody-drug conjugate will be a new standard of care in third-line TNBC, with potential in earlier treatment lines and in several other tumor types.
First COVID-19 Trial Success For Roche’s Actemra, But No Sign It Saves Lives
A composite endpoint conceals Actemra’s lack of mortality benefit – while life-saving dexamethasone gets EMA endorsement.
Moderna Expands Horizons With Vertex and Chiesi Deals
The world is waiting for Moderna’s COVID-19 vaccine results, but meanwhile the company is exploring new avenues to secure long-term growth